文献速递血栓与止血

PEITHO-2:中危急性肺栓塞早期转换为口服抗凝的4期试验

Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial.
PubMed 文献 · Lancet Haematol · 2021-08-04

PEITHO-2是一项多国单臂4期试验,纳入402例中危急性肺栓塞患者,先接受72小时肠外肝素治疗,后转换为口服达比加群150 mg每日两次。6个月内主要结局(复发性静脉血栓栓塞或肺栓塞相关死亡)发生率为2%,主要出血为3%。早期转换策略有效且安全,可优化资源并避免延长住院。

要点

  • 中危肺栓塞患者经72小时肠外抗凝后转换为达比加群,6个月血栓复发或肺栓塞相关死亡率为2%。
  • 所有主要结局事件均发生于中高危亚组(7/283,3%)。
  • 6个月主要出血发生率为3%,临床相关非主要出血为4%。

核心结论

  • 中危急性肺栓塞患者经标准临床评估后早期从肝素转换为达比加群是有效且安全的。

研究设计与样本

  • 多国、多中心、单臂4期试验,在奥地利、比利时、法国、德国、意大利、荷兰、罗马尼亚、斯洛文尼亚和西班牙的42家医院进行。
  • 患者先接受72小时肠外低分子量或普通肝素,后转换为口服达比加群150 mg每日两次。
  • 主要结局为6个月内复发性症状性静脉血栓栓塞或肺栓塞相关死亡,在意向治疗人群中评估。

主要发现

  • 6个月时,402例中11例(3% [95%CI 1-5])发生至少一次主要出血事件,16例(4% [2-6])发生至少一次临床相关非主要出血事件。
  • 唯一致命性出血发生于1例(<1%)患者,发生在转换为达比加群之前。
  • 中位随访217天(IQR 210-224),370例(92%)患者遵循方案。

临床怎么用

  • 中危急性肺栓塞患者可考虑短期肠外抗凝后早期转换为达比加群,以减少住院时间。
  • 治疗决策应结合标准临床评估,尤其需关注中高危亚组。

局限性

  • 单臂设计,无对照组。
  • 研究因数据安全与监测委员会建议,在预设中期分析后提前终止。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current guidelines recommend a risk-adjusted treatment strategy for the management of acute pulmonary embolism. This is a particular patient category for whom optimal treatment (anticoagulant treatment, reperfusion strategies, and duration of hospitalisation) is currently unknown. We investigated whether treatment of acute intermediate-risk pulmonary embolism with parenteral anticoagulation for a short period of 72 h, followed by a switch to a direct oral anticoagulant (dabigatran), is effective and safe. METHODS: We did a multinational, multicentre, single-arm, phase 4 trial at 42 hospitals in Austria, Belgium, France, Germany, Italy, Netherlands, Romania, Slovenia, and Spain. Adult patients (aged ≥18 years) with symptomatic intermediate-risk pulmonary embolism, with or without deep-vein thrombosis, were enrolled. Patients received parenteral low-molecular-weight or unfractionated heparin for 72 h after diagnosis of pulmonary embolism before switching to oral dabigatran 150 mg twice per day following a standard clinical assessment. The primary outcome was recurrent symptomatic venous thromboembolism or pulmonary embolism-related death within 6 months. The primary and safety outcomes were assessed in the intention-to-treat population. The study was terminated early, as advised by the data safety and monitoring board, following sample size adaptation after the predefined interim analysis on Dec 18, 2018. This trial is registered with the EU Clinical Trials Register (EudraCT 2015-001830-12) and ClinicalTrials.gov (NCT02596555). FINDINGS: Between Jan 1, 2016, and July 31, 2019, 1418 patients with pulmonary embolism were screened, of whom 402 were enrolled and were included in the intention-to-treat analysis (median age was 69·5 years [IQR 60·0-78·0); 192 [48%] were women and 210 [52%] were men). Median follow-up was 217 days (IQR 210-224) and 370 (92%) patients adhered to the protocol. The primary outcome occurred in seven (2% [upper bound of right-sided 95% CI 3]; p<0·0001 for rejecting the null hypothesis) patients, with all events occurring in those with intermediate-high-risk pulmonary embolism (seven [3%; upper bound of right-sided 95% CI 5] of 283). At 6 months, 11 (3% [95% CI 1-5]) of 402 patients had at least one major bleeding event and 16 (4% [2-6]) had at least one clinically relevant non-major bleeding event; the only fatal haemorrhage occurred in one (<1%) patient before the switch to dabigatran. INTERPRETATION: A strategy of early switch from heparin to dabigatran following standard clinical assessment was effective and safe in patients with intermediate-risk pulmonary embolism. Our results can help to refine guideline recommendations for the initial treatment of acute intermediate-risk pulmonary embolism, optimising the use of resources and avoiding extended hospitalisation. FUNDING: German Federal Ministry of Education and Research, University Medical Center Mainz, and Boehringer Ingelheim.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Klok FA, Toenges G, Mavromanoli AC, et al. Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial. Lancet Haematol. 2021. PMID: 34363769. doi:10.1016/S2352-3026(21)00203-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。